Market revenue in 2023 | USD 137.4 million |
Market revenue in 2030 | USD 555.9 million |
Growth rate | 22.1% (CAGR from 2023 to 2030) |
Largest segment | Pre-clinical |
Fastest growing segment | Pre-clinical |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Pre-clinical, Clinical |
Key market players worldwide | Lonza Group Ltd, Catalent Inc, Cytiva, Samsung Electronics Co Ltd, Thermo Fisher Scientific Inc, Novartis AG ADR, Wuxi AppTec Co Ltd, AGC Inc, OmniAb Inc, Rentschler Biopharma SE, Charles River Laboratories International Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell and gene therapy cdmo market will help companies and investors design strategic landscapes.
Pre-clinical was the largest segment with a revenue share of 66.23% in 2023. Horizon Databook has segmented the Canada cell and gene therapy cdmo market based on pre-clinical, clinical covering the revenue growth of each sub-segment from 2018 to 2030.
There is a notable trend toward outsourcing drug development and production, which is fueling the Canada cell & gene therapy CDMO market growth. Pharmaceutical companies are increasingly outsourcing these activities to CDMOs to leverage their expertise and specialized services.
Furthermore, CDMOs offer flexibility & scalability in manufacturing capacity, allowing pharmaceutical companies to adapt to changing market demand, manage fluctuations in product demand, and accelerate time-to-market for new therapies.
Some of the key companies providing pharmaceutical CDMO services in Canada are Bausch Health Companies Inc., Apotex Inc., and Patheon by Thermo Fisher Scientific, WellSpring Pharma Services, and Dalton Pharma Services.
Horizon Databook provides a detailed overview of country-level data and insights on the Canada cell and gene therapy cdmo market , including forecasts for subscribers. This country databook contains high-level insights into Canada cell and gene therapy cdmo market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account